Browsing by Author Park, Joong Won

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 3 of 3
TitleAuthor(s)Issue Date
 
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Journal:The Lancet
Yau, ThomasGalle, Peter R.Decaens, ThomasSangro, BrunoQin, Shukuida Fonseca, Leonardo G.Karachiwala, HatimBlanc, Jean FredericPark, Joong WonGane, EdwardPinter, MatthiasPeña, Ana MatillaIkeda, MasafumiTai, DavidSantoro, ArmandoPizarro, GonzaloChiu, Chang FangSchenker, MichaelHe, AiwuChon, Hong JaeWojcik-Tomaszewska, JoannaVerset, GontranWang, Qi QiStromko, CaitlynNeely, JaclynSingh, PriankaJimenez Exposito, Maria JesusKudo, Masatoshi
24-May-2025
 
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Journal:The Lancet Oncology
Yau, ThomasPark, Joong WonFinn, Richard S.Cheng, Ann LiiMathurin, PhilippeEdeline, JulienKudo, MasatoshiHarding, James J.Merle, PhilippeRosmorduc, OlivierWyrwicz, LucjanSchott, EckartChoo, Su PinKelley, Robin KateSieghart, WolfgangAssenat, EricZaucha, RenataFuruse, JunjiAbou-Alfa, Ghassan K.El-Khoueiry, Anthony B.Melero, IgnacioBegic, DamirChen, GongNeely, JaclynWisniewski, TamiTschaika, MarinaSangro, Bruno
13-Dec-2021
 
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Journal:Journal of Hepatology
Lau, GeorgeAbou-Alfa, Ghassan K.Cheng, Ann LiiSukeepaisarnjaroen, WattanaVan Dao, TuKang, Yoon KooThungappa, Satheesh ChiradoniKudo, MasatoshiSangro, BrunoKelley, Robin KateFuruse, JunjiPark, Joong WonSunpaweravong, PatrapimFasolo, AngelicaYau, ThomasKawaoka, TomokazuAzevedo, SergioReig, MariaAssenat, EricYarchoan, MarkHe, Aiwu RuthMakowsky, MalloryGupta, CharuNegro, AlejandraChan, Stephen L.
1-Jan-2024
Showing results 1 to 3 of 3